Skip to main content

FAQ

Sponsor FAQ

Concrete answers for sponsors evaluating Amavita Research as a Miami site for first-in-human, feasibility, and pivotal cardiovascular trials.

Cardiovascular research is our core, and our site now also takes on nephrology and neurology studies with affiliated investigators: nephrologist Dr. Robenson Jean-Marie and neurologist Dr. Delores Macksoud. Immunology and oncology are expansion areas through imaging-enabled subcontracted scopes, with Amavita as prime contractor and our affiliated imaging partner performing imaging. We are now recruiting partner practices in oncology, neurology, immunology, gastroenterology, rheumatology and other areas. See oncology expansion and neurology expansion.

Why Amavita Research vs. an academic medical center site?

Amavita Research is the clinical-research arm of amavita Heart and Vascular Health® — independent Miami cardiovascular practice; 16,000+ patients seen in the last 3 years. Investigators see eligible patients in clinic every day, so screening and enrollment ride on the same workflows as standard-of-care visits. No academic affiliation overhead, no internal politics around competing trials, no shared cath-lab schedules with surgical training programs. Single PI decision-speed, full FACC-credentialed roster, and ICH-GCP E6(R3)-compliant infrastructure.

Who are the principal investigators?

Dr. William W. O'Neill, MD, FACC — Chief Medical Officer & Senior Principal Investigator and interventional cardiologist with a structural-heart (TAVR) research background; PROTECT II national PI, PROTECT IV Steering Committee member, and PARTNER site PI at Henry Ford. Dr. Pedro Martinez-Clark, MD, FACC — Founder and Lead Investigator. Harvard-trained interventional cardiologist; Worldwide PI on the Percutaneous Mitral Valve Annuloplasty trial; helped develop the Trans-Caval TAVR approach. Dr. Hans C. Rutzen-Lopez, MD — Sub-Investigator, Cardiac Electrophysiology. Triple board-certified (Internal Medicine, Cardiovascular Disease, Clinical Cardiac Electrophysiology).

What therapeutic areas can Amavita Research run?

Cardiovascular is our core: coronary revascularization, structural heart (TAVR, mitral, tricuspid), heart failure, hypertension, peripheral artery disease and atherectomy, cardiac electrophysiology (atrial fibrillation, leadless pacing, VT ablation), pulmonary embolism response, and adjacent interventional cardiology indications. We also take on nephrology studies (CKD, diabetic kidney disease, cardiorenal, dialysis access) with nephrologist Dr. Robenson Jean-Marie, and neurology studies (stroke prevention, cerebrovascular disease, cognitive disorders) with neurologist Dr. Delores Macksoud. No nephrology or neurology study is enrolling yet. Imaging-heavy protocols (echo, CT angio, fluoroscopy) are supported through the in-network imaging infrastructure of amavita Heart and Vascular Health®.

How fast can Amavita Research get to first patient enrolled?

Time to first patient depends on the study, mostly on how quickly the sponsor contract and budget are agreed. A protocol that needs a net-new IRB submission takes longer. Patient screening starts the moment IRB approves — investigators screen candidate patients against active inclusion criteria during standard clinic visits.

How many patients can Amavita Research enroll?

Trial-specific, but Amavita Research has direct access to the patient panel across amavita Heart and Vascular Health® — independent Miami cardiovascular practice; 16,000+ patients seen in the last 3 years. Enrollment speed depends on the protocol's inclusion and exclusion criteria, and we estimate it for each study during feasibility. Sponsor receives weekly KPI dashboards via Monday.com showing screened, consented, and enrolled counts against target.

Are Amavita Research's investigators trial-active or just credentialed on paper?

Trial-active. Every PI at Amavita Research carries an active patient panel at amavita Heart and Vascular Health® clinics. Patients seen at clinic visits are screened against active trial inclusion criteria the same week. No 'rent-a-PI' arrangements, no investigator who hasn't run a cardiovascular trial in the last 24 months.

What quality and compliance certifications does Amavita Research carry?

IAOCR GCSA-certified (recertified May 13, 2026, valid to Feb 28, 2027) (Global Clinical Site Assessment standard). IAOCR WPQC Gold for workforce. ICH-GCP E6(R3) compliant SOPs across the full study lifecycle. Society for Clinical Research Sites (SCRS) member. SOP SITE-107 (KPI tracking and audit trail) enforced on every active study. See /certifications for full assessment scope and modules met.

How does Amavita Research handle source data verification and monitoring?

Designated CRC ownership per protocol, Monday.com-tracked KPIs for visit-window adherence, dedicated office space and badge access for sponsor monitor visits, prep packets shipped to monitors before each visit. Source data is verified weekly internally before sponsor monitor arrival, with deviation reports generated automatically.

What's Amavita Research's audit and inspection history?

Sponsors can request available quality and audit documentation during feasibility.

Can Amavita Research support hybrid US + Latin America trial designs?

Yes. Amavita Research operates in tight integration with bioaccess®, the first-in-human CRO for the Americas led by Amavita's CEO Julio G. Martinez-Clark. Sponsors can run a US arm at Amavita Research while bioaccess simultaneously runs a Latin American arm under the same protocol — FDA-ready data on both sides, single sponsor relationship, accelerated total enrollment.

What's the cost compared to other Miami cardiovascular sites?

Budgets are scoped per protocol at feasibility.

Who owns the data, IP, and trial results?

The sponsor. Amavita Research operates as a contracted clinical research site only. The sponsor retains the protocol, data, and any IP arising from the study; Amavita Research is responsible for site-level execution and source documentation. Site closeout transfers all source records, the trial master file, and electronic data to the sponsor in their preferred format.

Can Amavita Research support imaging-heavy trials?

Yes. The site has on-network access to the imaging infrastructure of amavita Heart and Vascular Health® — echocardiography, fluoroscopy, CT angiography. Sponsor-specific imaging core labs are accommodated. The site is comfortable with imaging adjudication pipelines including DICOM transfer protocols and de-identification workflows required for blinded core lab review.

How do I start a conversation with Amavita Research about a trial?

Email julio@amavita.health or call 954-903-7210; see amavitaresearch.com/contact-sponsor. The first conversation is typically a 30-minute feasibility call covering indication, inclusion criteria, sample size, and timeline. We respond promptly. Under MNDA we can share investigator CVs, site qualification packets, and prior-trial enrollment metrics.

Ready to evaluate Amavita Research?

Start a 30-minute feasibility conversation with our sponsor team.